We are thrilled to have been at #ATS2024 and our presence has further highlighted the importance of the work we are doing to prevent and change the course of respiratory diseases.

gsk.to/3QZjYex

“We need nature to tackle climate change and we can’t halt and reverse nature loss without a stable climate”

Check out this FT article, in partnership with GSK, and discover why healthy people need healthy ecosystems. gsk.to/3wLMAB4

As #ATS2024 comes to a close, read about why our timely implementation of evidence-based treatment plans are important in preventing deterioration in health, preventing exacerbations and disease progression.
gsk.to/3wLER6a

We are proud to be a leader in the field of asthma research and of the ongoing contribution we are making to deliver next generation treatment goals and help ease the burden of asthma on millions of people with asthma. #ATS2024

Learn more here: gsk.to/3KaR07J

Together with @WBCSD, we’re convening the pharma sector to advance our understanding of the sector’s relationship with nature. Through collaboration, we aim to identify and accelerate the priority actions that we can take together to protect nature and our businesses.

Today, our #NatureStrategy has been recognized by Business for Nature as part of ‘ #NowforNature ’, which calls on businesses to act on nature and boost resilience to nature related risks.

Find out more about why nature it not only fundamental for human health, but it’s also critical

Our CEO, Emma Walmsley, attended the The Royal Society event on #antimicrobialresistance alongside HRH Prince William, Prof. Dame Sally Davies & other leaders.

The event reinforced the need for collective action, like our #FlemingInitiative partnership, in tackling #AMR : gsk.to/3Kp9FwV

Our understanding of asthma has advanced and treatment options are helping to achieve ambitious goals. We are proud to be a leader in this field and the ongoing contribution we are making to deliver next generation treatment goals for the millions of people with asthma.

This World Day for Cultural Diversity, we’re highlighting the importance of ensuring people most impacted by a particular disease are included in clinical research.

Watch Maimah Karmo's story to learn how we’re working with Tigerlily Foundation to help achieve equitable health outcomes.

#News for #investors and #media : Today we have announced positive results for the first phase III trials in #asthma of one of our pipeline biologics.

Learn more here: gsk.to/3KgCKKx

We’re aiming for people with severe asthma to achieve clinical remission, freeing them from exacerbations or the need for oral corticosteroids ─ achieving symptom control and stabilising lung function.

Find out who could achieve remission ☟
gsk.to/3wwgYPX

#Asthma management is evolving. A simple blood test can identify the underlying pathology driving an individual’s asthma and help to optimise their treatment.

#ATS2024 learn how biomarkers aid treatment decisions.
gsk.to/3UXGs21

#Asthma management is evolving. Dr Eduardo Genofre, VP Global Medical Affairs explains how a simple blood test can identify the underlying pathology driving an individual’s asthma and help to optimise their treatment and ease the burden. #ATS2024

Timely intervention with the right management strategy can help to prevent exacerbations which can lead to cumulative lung damage and disease progression in #asthma and #COPD .

Discover more in our latest article: gsk.to/3wxZ3bD

We are sharing our industry-leading respiratory portfolio by talking to leaders, advocates and partners about respiratory and prevention to change the course of disease #ATS2024

gsk.to/3WTeLcd

People with #RefractoryChronicCough experience a persistent cough lasting for over 8 weeks despite treatment for an identified underlying medical condition or when one isn’t identified despite appropriate evaluation.

At #ATS2024 , experts will discuss this unmet need.

We are excited to be at #ATS2024 , where we will be showcasing our work to redefine the future of respiratory care and improve the lives of millions.

Follow us for more. gsk.to/3ReVApF